7:59AM EpiCept and Immune Pharmaceuticals agreed to merge (EPCT) 0.13 : Immune Pharmaceuticals, a privately held Israeli com, and EpiCept announced earlier that they have entered into a definitive merger agreement. The transaction is anticipated to close during the first quarter of 2013 and is subject to satisfaction of certain customary closing conditions, including the approval of a majority of EpiCept shareholders. The combined com, to be named Immune Pharmaceuticals, will be primarily focused on developing antibody therapeutics and other targeted drugs for the treatment of inflammatory diseases and cancer.
Market Data 
Markets 
AI
